OBJECTIVES: Proton pump inhibitors (PPIs) are the treatment of choice for gastroesophageal reflux disease (GERD), yet many patients experience persistent symptoms. To date, the burden of illness (BoI) among partial responders to PPI treatment is not well understood. METHODS: REMAIN-France was a multicentre, 12-month prospective study of adults with GERD who were newly identified as partial responders to optimised PPI treatment. BoI was evaluated at baseline, 3, 6, 9 and 12 months via patient-completed questionnaires, including the Reflux Symptom Questionnaire with 7-day recall (RESQ-7). Medical evaluations were completed at baseline, 6 and 12 months. Healthcare consumption was evaluated in terms of visits to a primary care physician (PCP) and gastroenterologist, number of endoscopies and days on prescribed GERD medication. All analyses were descriptive. RESULTS: A total of 262 patients were enrolled (mean age, 54y; 40.5% men), the majority of whom (nϭ226, 86%) completed the 12-month study. Using the RESQ-7 questionnaire, 32% of patients reported severe symptoms and 48% reported daily symptoms at baseline despite PPI treatment. Whilst continuing to receive prescribed GERD medication (most commonly daily PPIs), symptoms remained burdensome at 6 and 12 months and indicated a positive relationship with impaired quality of life (SF-36, EQ-5D) and decreased work productivity (WPAI-GERD). Between baseline and 6 months, the mean number of visits to a PCP and gastroenterologist among all patients was 1.9 and 0.5, respectively. For 7-12 months' follow up the corresponding figures were 1.8 and 0.4, respectively. A total of 12 patients (4.6%) underwent endoscopy in the first 6 months of follow-up; thereafter, 10 patients (3.9%) underwent endoscopy between 7 and 12 months. CONCLUSIONS: In French patients with GERD who have persistent symptoms despite PPI therapy, the symptom burden is substantial and a positive relationship with impaired quality of life and decreased work productivity is indicated.
OBJECTIVES: Flu-like symptoms (pyrexia, chills, myalgia and arthralgia) are experienced by 30%-50% of chronic hepatitis C (CHC) patients undergoing combination interferon and ribavirin (RBV) treatment and are often cited as reasons for discontinuation. To track these symptoms, the Hepatitis Physical Symptom Severity Diary (HPSS-D), was developed. METHODS: Four items from the HPSS-D comprise the Flu-Like Symptom Index (Index): fever, chills, muscle aches/pain, and joint pain. Response options ranged from 0 (no symptoms) to 10 (worst symptom/problem) over the past 24 hours. The diary was completed for 7 consecutive days at baseline and weeks 4, 8 and 12. Data from two Phase 2b studies of treatment-naïve patients comparing pegIFNalpha2a/RBV (peg-alfa) to peg-INF Lambda/RBV (peg-lambda) and peg-alfa to peg-alfa and direct acting antiviral were combined. Measurement properties were assessed. Mean and change scores and proportions of patients reporting flu-like symptoms were calculated. RESULTS: Measurement properties of the Index were supported with test-retest ICC value of 0.85, Cronbach's alpha range: 0.73-0.81, low to moderate construct validity [range: 0.23-0.63], and demonstrated known groups validity (based on physician-reported flu symptoms). Responsiveness coefficients suggested a small to medium effect (SESϭ0.40; SRMϭ0.39). MIDs were 2.5-3.0 points. Mean Index scores at week 12 for the peg-alfa group (Nϭ36) increased from baseline by 2.39 Ϯ 4.95 versus 0.83 Ϯ 5.05 for peglambda patients (Nϭ26). The percentage reporting any flu-like symptoms was significantly higher for peg-alfa (75%) versus peg-lambda patients (27%) at week 12, (pϽ0.001), despite similar baseline rates. Fewer peg-lambda versus peg-alfa patients (50% versus 82%) experienced clinically significant worsening of flu-like symptoms. CONCLUSIONS: PRO measures are important parameters to gauge patients' experience with treatment, providing systematic assessment of treatment benefit and side effects. This new Flu-Like Symptom Index from the HPSS-D demonstrated adequate measurement properties and detected lower intensity and frequency of flu-like symptoms for peg-lambda versus peg-alfa patients. (kidney, liver, heart or lung) . METHODS: Two phases: the Mypaciente-1 study was an epidemiological, crosssectional, multicentre study in which the SIGIT-QoL® questionnaire (17 items) was developed and its reliability, feasibility and validity (content and construct) were proven. At second, an observational, prospective, multicentre study, the Mypaciente-2, was implemented to assess the test-retest reliability and the sensitivity to change of the SIGIT-QoL®. SOT patients agedՆ18, who had received the graft 3-24 months before and suffering from GI, were evaluate at baseline, 1-2 weeks and 3 months after baseline. Data recorded: age, sex, SOT type, acute allograft rejection (AAR), GI etiology, Clinical and Patient global Impression scale (CGI-SI&GI and PGI-SI&GI) and the SIGIT-QoL® (range: 0-maximum impact to 68-minimum disruption). Intraclass correlation (ICC), differences between baseline and last visit (Wilcoxon test), effect size (Cohen's d), the minimal important difference -MID-(using CGI & PGI as anchors in General Linear Models) and the cut-off score (ROC analysis) were calculated. RESULTS: In the Mypaciente-2 study 277 SOT patients (61.4% males) were included. Mean age (SD) was 52.69(11.65) years, time since transplantation was 12.31(6.74) months and 22.4% suffered AAR. At baseline, SIGIT-QoL® scores: 51.21(11.25) showed an impact on patients' HRQoL that diminished 3 months later: 57.40(8.38;pϽ0.001) . SIGIT-QoL® test-retest reliability was adequate (ICCϭ0.740-0.895). A high-moderate effect size (dϭ-0.590) was found. Moreover, MID of 4.2 points in total scores were found (F4,223ϭ16.917,pϽ0.001 and F4,224ϭ25.138,pϽ0.001). Finally, a cut-off point (55.00 points) was estimated (AUCϭ0.846,pϽ0.001; sensitivityϭ0.793; specificityϭ0.713; negative likelihood ra-tioϭ0.290; positive likelihood ratioϭ2.762). CONCLUSIONS: The SIGIT-QoL® is a feasible (average completion time lower than 6.5 minutes), reliable and valid instrument for assessing the impact of GI symptoms on SOT patients.
PGI26 EVALUATING THE IMPACT OF GASTROINTESTINAL EPISODES ON THE HEALTH-RELATED QUALITY OF LIFE OF SOLID ORGAN TRANSPLANT RECIPIENTS: VALIDATION OF THE SIGIT-QOL® QUESTIONNAIRE -THE MYPACIENTE 1 & 2 STUDIES

PGI27 SLEEP DISTURBANCE AND QUALITY OF LIFE AMONG HEPATITIS C INFECTED INDIVIDUALS
Wagner JS, Gross HJ, DiBonaventura MD Kantar Health, New York, NY, USA OBJECTIVES: Hepatitis C virus (HCV) infection is associated with fatigue, anxiety, and depression. Little is known, however, about the effect of sleep disturbances on health-related quality of life (HRQoL), and what factors are associated with such disturbances. METHODS: This study is based on data from the EU National Health and Wellness Survey (Nϭ57,805), a cross-sectional database representative of the adult EU population. Patients who reported being diagnosed with HCV by a physician and provided household income and body weight information were included for analysis (Nϭ301). Patients who reported experiencing insomnia or sleep difficulty symptoms in the past year (nϭ135) were compared with patients who did not experience such symptoms (nϭ166). Sleep group membership was predicted with a logistic regression model, while mental and physical HRQoL (SF-12) were predicted with multiple regression models. Covariates included age, gender, marital status, education, income, employment, BMI, exercise and smoking habits, alcohol use, and physician diagnosed HIV/AIDS, hepatitis B, anxiety disorder, and depression. RESULTS: HCV patients with sleep disturbances were significantly younger (48.8 vs. 51.7) and more likely to be diagnosed with HIV/AIDS (8.1% vs. 2.4%), an anxiety disorder (56.3% vs. 22.9%), and depression (48.9% vs. 10.8%) (psϽ0.05) than patients with no sleep disturbances. After controlling for potential confounders, anxiety disorder (ORϭ2.2) and depression (ORϭ5.1) were the only significant predictors of sleep disturbances (psϽ0.05). SF-12 mental HRQoL scores were significantly associated with age (bϭ0.2), anxiety disorder (bϭ -5.7), depression (bϭ -5.9), and sleep disturbances (bϭ -5.1, psϽ0.05). SF-12 physical HRQoL scores, however, were not associated with sleep disturbance. CONCLUSIONS: Despite the strong association of anxiety disorder and depression with sleep disturbances among HCV-infected individuals, sleep disturbances had an independent and significant effect on mental HRQoL in this population. The results suggest effective treatment of disturbed sleep may improve the quality of life of HCV patients.
PGI28
DISEASE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH QUIESCENT ULCERATIVE COLITIS: EFFECTS OF ONE YEAR MAINTENANCE TREATMENT WITH MMX MESALAMINE
For the overall patient sample, no statistically significant changes across visits was observed for any SIBDQ domain or total score (all PϾ0.05); mean change from baseline to endpoint did not exceed 3% for any SIBDQ score. At endpoint, patients exhibiting recurrent UC (nϭ29) scored significantly lower than non-recurrent patients (nϭ117) on bowel symptoms, emotional function, and social function domains and total score (PϽ0.001 for all differences). CONCLUSIONS: Patients with quiescent UC receiving daily treatment with MMX mesalamine (2.4 g/day) exhibited high stability, and thus strong maintenance, in disease-specific HRQoL over the course of one year. The majority of patients remained in clinical remission following one year of this treatment regimen. Patients with clinically recurrent UC showed significantly worse HRQoL outcomes than non-recurrent patients.
PGI29
QUALITY OF LIFE IN CHRONIC LIVER DISEASE
Anapaz V 1 , Vicente C 2 , Almeida A 1 1 Universidade da Beira Interior, Covilhã, Portugal, 2 Centro Hospitalar Cova da Beira, Covilhã, Portugal OBJECTIVES: Chronic liver disease is responsible for approximately 40,000 deaths annually, which corresponds to about 2% of all deaths worldwide. This study aimed to specify and understand the characteristics of patients with LC service followed in the Gastroenterology at CHCB as well as assess the severity of LC using the scale of Child-Pugh-Turcotte and the Health Related Quality Of Life. METHODS: This is a retrospective, observational and cross for the evaluation of QdVS a group of patients diagnosed with LC in CHCB. Direct interviews were carried out using questionnaires to a sample of 42 patients with clinical and imaging during the months of January and April 2011. Besides the descriptive analysis we tried to establish some correlations between the variables studied, considered statistically significant when p value is Ͻ0.05. RESULTS: The mean age of study participants was 62 years, and approximately 31% of patients were between 66 and 75 years. The males and ethylic etiology of cirrhosis accounted for a proportion of over 90% of all patients. The average score obtained after applying the SF-36 was around 49%. After the calculation made to stratify the severity of the disease across the range of CPT, 69% of patients were in class A, class B 21% and 10% to class C. CONCLUSIONS: The LC mainly affects males, and regular alcohol consumption the predominant etiology. Regarding the scale of CPT, the results indicate a good survival. We conclude that the QdVS is clearly affected in CLD associated with LC, particularly in terms of physical pain, physical performance and vitality. This study is consistent with national data, where the Liver Cirrhosis is a public health problem, for which measures must be taken concerning the excessive consumption of alcoholic beverages.
PGI30
COMPARISON OF HEALTH RELATED QUALITY OF LIFE BETWEEN HEPATITIS, CIRRHOSIS, LIVER TRANSPLANTATION AND HEPATIC CARCINOMA: RESULTS OF THE COME STUDY
Ciampichini R Charta Foundation, Milano, Italy OBJECTIVES: As a result of successful treatments for chronic hepatic diseases (CHDs), patients generally live longer but often with a compromised wellbeing. We assessed Health-Related Quality-of-Life (HRQoL) of CHDs adult patients. METHODS: A naturalistic multicentre Cost-of-Illness study was conducted. Adult patients (ageϾ18 years) diagnosed with CHDs, consequently accessing at gastroenterology unit of 2 hospitals, were enrolled. Direct, indirect and intangible costs were estimated from the societal perspective. The patients were sub-grouped according to their main condition at the enrollment: hepatitis B and/or C, cirrhosis, liver transplantation, hepatic carcinoma. HRQoL was assessed with the EQ-5D 3L and 5L versions (the psychometric properties of the 5L new version was previously discussed: podium by Scalone et al, 13th ISPOR Congress 2011, Prague). The following results pertain the EQ-5D-5L results. RESULTS: We enrolled 1,088 valid patients, 62% male, aged 19-90 (medianϭ60) years. Patients with hepatitis were 60.4%, 20.2% had cirrhosis, 11.9% had liver transplantation, 7.5% hepatic carcinoma. Among all the patients, the meanϩSD VAS was 69.1ϩ20.8. Mobility was an extreme/severe problem for 3.3% and a moderate/slight problem for 22.6% of the patients. Self-care was an extreme/severe problem for 1.2% and a moderate/slight problem for 11.5% of the patients. Usual activities was an extreme/severe problem for 4.0% and a moderate/slight problem for 25.5% of the patients. Pain/discomfort was extreme/ severe for 3.2% and a moderate/slight problem for 36.1% of the patients. Anxiety/ Depression was extreme/severe for 4.5% and a moderate/slight for 43.5% of the patients. Patients with cirrhosis reported the worst levels of HRQoL, those with carcinoma had a worse HRQoL than patients with transplantation, those with hepatitis reported better levels of HRQoL. CONCLUSIONS: Our study shows how HRQoL is negatively related with the severity and chronicity of CHDs. Health technology aimed to improve wellbeing in patients with disabling long term hepatic disease is required.
PGI31 THE MAINTENANCE OF WORK-RELATED PRODUCTIVITY DURING ONE YEAR OF MMX MESALAMINE TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS
Yen L 1 , Yarlas A 2 , Hodgkins P 1 , Solomon D 3 , Karlstadt R 3 , Kane SV 4 1 Shire Development, Inc., Wayne, PA, USA, 2 QualityMetric Incorporated, Lincoln, RI, USA, 3 Shire Pharmaceuticals, Wayne, PA, USA, 4 Mayo Clinic, Rochester, MN, USA OBJECTIVES: Ulcerative colitis (UC) impairs patients' productivity in the workplace. While studies have shown increased productivity in patients with active UC following treatment with a multi-matrix (MMX) oral formulation of mesalamine, the current analysis is the first to examine maintenance of work-related outcomes (WRO) in patients with quiescent UC who received one year of MMX mesalamine treatment. METHODS: Data were from a multicenter, open-label study of patients with quiescent UC who received MMX mesalamine 2.4 g/day QD for twelve months. The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP), administered at baseline, six-month, and twelve-month visits, measured the impact of a patient's UC on 4 domains: absenteeism, presenteeism, overall productivity, and impairment in non-work activities. Repeated-measures analysis of variance assessed change in scores across visits. Analysis of covariance assessed the association between WRO and disease activity (covariates: age, gender, and BMI) by comparing WPAI:SHP scores between patients with clinically recurrent and non-recurrent UC at 12 months. RESULTS: WPAI:SHP scores were collected from 198 patients at baseline, 142 patients at six months, and 154 patients at 12 months/early withdrawal (endpoint). Stability of WRO across 12 months for the overall sample was evidenced by baseline-endpoint changes in mean scores of Ͻ2% for each WPAI:SHP scale, with no statistically significant differences across visits (all PϾ0.05). Patients with clinically recurrent UC at month 12 (nϭ29) scored significantly worse than non-recurrent UC patients (nϭ113) on presenteeism, overall productivity, and activity impairment, PϽ0.05 for differences. CONCLUSIONS: Patients with quiescent UC who received MMX mesalamine 2.4 g/day QD showed stable WRO over the course of one year. Findings indicate that long-term MMX mesalamine treatment was associated with maintenance of WRO for patients with quiescent disease. This treatment regimen maintained clinical remission for the majority of patients, with recurrent patients showing worse WRO than non-recurrent patients.
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PGI32 AN INVESTIGATION INTO THE EXTENSIVE SPECTRUM OF AGENTS USED FOR THE MANAGEMENT OF POST-OPERATIVE ILEUS
Richard L 1 , Kusel J 2 , Hamerslag L 2 , Leonard SA 2 1 Norgine Limited, Uxbridge, -, UK, 2 Costello Medical Consulting Ltd, Cambridge, UK OBJECTIVES: Regardless of the wide variation in estimated incidence rates for post-operative ileus (POI), it is widely understood that gastrointestinal complications represent the most common post-operative morbidity type. In addition to the patient burden, the extension of hospital stay caused by POI (estimated to be between 3.2 and 8 days) can have an enormous economic impact, making this an important area of research. The objective of this literature review was to explore the various interventions investigated for the acceleration of gastrointestinal recovery after surgery and reduction of POI. METHODS: Comprehensive literature searches across online databases and horizon scanning were used to identify relevant literature. Literature was gathered on any intervention that had been assessed in a randomised clinical trial for the treatment of POI following abdominal surgery. RESULTS: Over 600 studies were identified as potentially relevant. Approximately one quarter of these assessed the broad spectrum of prokinetic pharmacological agents for the treatment of POI, as well as antiemetics, antibiotics and anaesthetics. In particular, research into new ghrelin agonists is underway. Next to this, the unfavourable effects of opioid analgesics on GI recovery were studied in numerous trials. Non-pharmacological methods to enhance recovery after surgery such as gum chewing, acupuncture and early feeding have also been investigated with mixed success. Many of the trials identified were dated, illustrating how long POI has remained an unresolved issue for clinicians and patients. CONCLUSIONS: Many different types of treatment, with varying mechanisms of action, have been clinically studied for the prevention or treatment of POI over the past 40 years. However, there is still no standard management paradigm to accelerate post-operative bowel recovery. The absence of an effective pharmacological agent licensed for this indication in Europe and significant variance in practice suggest an unmet clinical need, which should shape future research in this area.
PGI33
PREDICTORS OF DIRECT MEDICAL COSTS OF CROHN'S DISEASE AND ULCERATIVE COLITIS
